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Abstract
Bacteriophages represent a large portion of the biomatter on our planet, and many
of them have yet to be fully characterized. Here we discuss the proteomic analysis of a
particular Bacteriophage, Mycobacteriophage CrimD. This phage was discovered on the
Campus of William & Mary and has had its genome characterized. We took the next
logical step of proteomic analysis.
In our analyses we made use high pressure liquid chromatography paired with
linear ion trap mass spectrometry to analyze the proteome of CrimD at specific time points
after the infection of its host, Mycobacterium smegmatis. Additionally, we used nanospray
ionization with in-house produced analytical columns and emitters to analyze our
samples. These techniques had been previously used in our lab to analyze different
bacteriophages but required significant optimization in order to successfully analyze
CrimD.
In our analyses we found that we are able to see different proteins being expressed
in the different time samples. Consequently, we were able to assign each time point to
represent a different phase in the replication cycle of CrimD, namely the lysogenic and
Early and Late lytic phase of replication. We were also able to assign many proteins with
unknown function to specific time points, opening the door for further characterization of
these proteins and CrimD.
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Chapter 1. Introduction
1.1.

Introduction to Bacteriophages

1.1.1 General Introduction
Bacteriophages, or phages, represent a significant portion of the biological material
on our planet. A bacteriophage is, simply put, a virus that infects bacteria. The number of
bacteriophages on the planet is estimated to be on the order of 1031 1 and 1025 new
bacteriophage infections take place every second.2 The vast scale of bacteriophages
begins to reveal the outsized impact that they have on microbial ecosystems. Phages
play a role in regulating microbial ecosystems as diverse as the Pacific Ocean to a
tuberculosis infection. Phages have long been of interest to science due not only to their
outsized role in microbial life, but also their potential applications to humans. Phages have
been used historically to treat diseases and have been proposed as potential alternatives
to antibiotics for some diseases.3,4 Additionally, nearly one in three bacteriophage
proteins have no known homologs.5 Viruses represent an enormous reservoir of genetic
diversity, much of which has yet to be fully characterized. For example, when first
identified, over half of SARS-CoV2 proteins were not fully characterized.6 Study of
viruses, and more specifically bacteriophages, is key to furthering understating of this
enormously diverse and impactful group of biological entities.
At a basic level all viruses function the same way, they are obligate cellular
parasites that hijack host cellular machinery to replicate their genomes and produce new
viral particles. Bacteriophages do this by “injecting” their genetic material, most often
dsDNA, through the host cell wall from where it interacts with host transcription/translation
machinery beginning the infectious cycle. Many bacteriophages can replicate in two ways;
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first by replicating their genome and producing new viral particles that lyse the host
releasing the virions to infect new hosts. Secondly, Bacteriophages may insert their
genome into the host’s genome, from where it is replicated along with the host’s genome.
This combination of virus-host is termed a “lysogen”. The first method of replication is
termed “lytic” while the second is “lysogenic”. All bacteriophages can undergo lytic
replication, while only some can also undergo lysogenic replication. Those that can
undergo both lytic and lysogenic replication are termed “temperate” phages. The
lysogenic replication cycle allows a virus to hold off on releasing its progeny until it is
under ideal conditions. 7
1.1.2 Introduction to the Phage Lab at W&M and CrimD
In our experiments, we investigated a bacteriophage named CrimD that was first
discovered in 2008 by Hilary Whelan as part of the William & Mary Phage Lab.8 The
Phage Lab at William & Mary is part of a program sponsored by the Howard Hughes
Medical Institute. The Phage Lab involves a group of freshman searching around campus
for phages that infect the nonpathogenic model of tuberculosis, Mycobacterium
smegmatis. One of the phages is chosen to have its genome sequenced and full
bioinformatics and gene mapping is performed as part of the lab. CrimD was the first
phage that was fully sequenced as part of this project.9 Since then, the collection of
phages from this lab has grown dramatically. We are expanding on this project by taking
the next logical step in characterizing these isolated phages: protein identification and
differential expression.
1.1.3 Introduction to Mycobacteriophage CrimD
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CrimD belongs to a family of viruses named Caudovirales, or tailed
bacteriophages. Caudovirales are distinguished by their long “tail”, they share a common
origin, and their genetic information is in the form of dsDNA, under the Baltimore
classification of virus, they are type 1.
They are the viruses one typically imagines when picturing a phage.10 As it can
infect mycobacteria, CrimD belongs to the mycobacteriophage group of viruses.
Mycobacteriophages are known to often be able to infect multiple members of the
mycobacterium genus. CrimD specifically belongs to a “cluster” of closely related phages
called K1. 8,11 K1 phages are temperate phages.
Mycobacteriophage CrimD has 95 genes, numbered 1-96 (there is no gene 5).11
The vast majority of CrimD genes are on the same strand of DNA, with only 3 being read
on the opposite strand. Of the 95 genes, 91 have been assigned to Phamilies, that is,
clusters of closely related genes across different phages. The remaining 4 are orphan
genes with no known counterparts in any other phage.

Figure 1.1- Scanning Electron microscope image of mycobacteriophage CrimD.11
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1.2. Introduction to Proteomics
1.2.1 General introduction to Proteomics
The complete genome of an organism is not sufficient to fully understand what
happens in vivo. Depending on the organism, some genes may not be expressed as
proteins and/or may be modified in some way from the original genetic code. For this
reason, we study the proteome, the whole collection proteins expressed in a cell.12 By
extension we will define proteomics for the purposes of this paper to mean the study of
the proteome. Proteomics can take several different forms. A prominent example of this
is full proteome discovery where the goal is to determine every protein expressed in a cell
at a given time. This technique was only made possible by recent advances in technology
such as the ultra-high resolution mass spectrometer(MS).13 Full proteome discovery is
often paired with multiple levels of separation, e.g., SDS-PAGE (sodium dodecyl sulphate
polyacrylamide gel electrophoreses followed by chromatography), in order to identify the
lowest abundance proteins.13
Full proteome discovery can be contrasted with targeted proteomics. Targeted
proteomics has expanded to encompass a wide variety of techniques but can be roughly
thought of as any technique where specific proteins of interest are screened out of the
sample. This generally requires greater knowledge of the sample beforehand, as it is not
possible to screen for a protein that one does not know exists.14 Targeted proteomics can
be performed in such a way that only a specific protein of interest is analyzed, such as by
using SIM (selected ion monitoring) in mass spectrometry, or alternatively can be
performed after the

primary analysis, where only specific proteins of interest are

screened in a much larger sample.14 The line between these techniques has, in recent
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years, been blurred to some extent as it is now possible to perform targeted proteomics
on such a variety of proteins as to analyze the whole proteome.15 Many of these
techniques rely heavily, if not entirely, on mass spectrometry, which has become a critical
component of modern proteomics.

1.2.2 Introduction to Mass Spec Based Proteomics
Mass spectrometry-based proteomics is performed, as the name suggests, with a
mass spectrometer (MS) as the detector. Proteins must first be separated, either by
PAGE or by chromatographic means and then ionized prior to analysis in order to be
identified.
Mass spectrometry allows for the proteins or peptides of interest to be identified by
their overall mass to charge ratio (m/z) and the m/z of their fragments. This technique is
termed tandem mass spectrometry. In tandem mass spectrometry, also called MSn, the
analyte is first isolated based on its mass to charge ratio then fragmented by some means
and the fragment is isolated and can then, depending on the instrument, be fragmented
again.16
1.2.3 Introduction to Top-Down Proteomics
Mass spectrometry-based proteomics can be roughly divided into two categories,
bottom-up proteomics, and top-down proteomics. Bottom-up proteomics involves either
the digestion of all the proteins in a sample, termed “shotgun” proteomics, or the digestion
of targeted proteins from a gel or other separation followed by the analysis of the peptides.
As this is the method that we use, it will be discussed in detail later17. In contrast, topdown proteomics involves mass spectrometric analysis of intact proteins usually following
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some separation step - either by chromatography or by gel electrophoresis. Top-down
proteomics can have many advantages, such as a superior ability to detect posttranslational modifications and the preservation of some protein-protein interactions. The
primary disadvantage is that very high-resolution MS is required. Top-down proteomics
can also be far slower than bottom-up proteomics18 Top-down proteomics also requires
proteins to be fragmented in the gas phase, which can be difficult for many proteins.17
1.2.4 Introduction to Bottom-up Proteomics
In our lab, we have an LTQ linear ion trap mass spectrometer that does not have
the resolution or mass range required for top-down studies. Rather, we use the bottomup approach in which the protein(s) of interest are first digested into shorter peptides
before mass spectrometric analysis. Digestion is accomplished using enzymes, such as
trypsin, that cleave the proteins at predictable and consistent sites. For example, trypsin
cleaves C-terminal to basic residues Lys and Arg. The resulting peptides are then
analyzed and identified using analytical techniques, most commonly high-pressure liquid
chromatography in combination with mass spectrometry. In the chromatography step, the
peptides are typically separated based on polarity, and then analyzed by MS-MS.
Ultimately, each peptide can be identified accurately because small peptides have
predictable fragmentation patterns.19 The experimental fragmentation pattern for each
peptide is compared with a computationally predicted fragmentation pattern and a cross
correlation “score” is assigned.17 The proteins are then identified by comparing identified
peptide sequences to known sequences from a database file. Mass spectrometry has
increased in usefulness in recent years corresponding with the dramatic increase in the
power of mass spectrometry.
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1.3 Introduction to Mass Spectrometry
Mass spectrometers are powerful tools that allow analytes to be analyzed by their
mass to charge ratio (m/z). The first MS was developed in 1912 by JJ Thomson, as part
of his work on cathode ray tubes. Since then, the complexity and variety of MS has
exploded. All MS, even Thomson’s original, have the same components; an ionization
source to produce gas phase ions out of the analyte, a mass analyzer that separates the
ions based on m/z, and a detector. In proteomics studies the ionization sources are
typically electrospray ionization (ESI), or matrix assisted laser desorption ionization
(MALDI) or some variation on those techniques.17,18
1.3.1 Electrospray Ionization
While MALDI ionization offers several advantages to ESI, its primary limitation is
that it does not couple with HPLC methods for high-throughput analyses. For this reason,
ESI is the dominant source for both top-down and bottom-up proteomics studies.17,18 The
principle of ESI was first published in 1990 by John Fenn, and involves a sample in
solution containing some adduct, such as protons from an acid, being eluted from a
capillary into an electrode with a strong voltage potential applied (on the order of kV)
opposite the instrument source, which is usually grounded. As the sample elutes, the
voltage potential causes the sample to spray into a fine mist, which is then hit with an
inert gas, which causes desolvation of the droplets. The charged particles will migrate
due to the electric potential towards the inlet of the instrument. These particles are gasphase ions and can then be analyzed by MS.20,21 ESI has the distinct advantage of having
a very high ionization efficiency, that is, the ratio of sample in the solution to sample that
is ionized is high. ESI also allows for the consistent ionization of very large ions,21 which
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makes it ideal for proteomics as it allows one to confidently analyze the entire sample
with minimal missed peptides or proteins.
1.3.2 Nano-spray ionization
A commonly used variation of ESI is nano spray ionization (NSI). NSI functions
under the same basic principles as ESI, but the flow rates are much lower, typically 2-3
orders of magnitude lower, and no gas flow is used. The capillary inner diameter is much
smaller, and comes to a very fine point, on the order of 5-10 microns, the tip of which is
called the emitter. The very small emitter causes the spray droplets to be smaller than
those formed by ESI, and they can be broken apart by electrostatic forces, hence the lack
of a gas flow.21,22 NSI has several distinct advantages over ESI, apart from the lack of a
gas flow. These include a stronger resistance to contamination, that is, adducts of
contaminants and analyte molecules are less likely to be seen. Additionally, NSI
maintains a very high ionization efficiency, nearly 100%, and a very high portion of those
ions can be trapped in the MS yielding a higher dynamic range.22
1.3.3 Linear Ion Trap Mass Spectrometers
It is also necessary to introduce linear ion trap mass spectrometry as it is the
technique used to perform all of our analyses. A linear ion trap mass spectrometer (LIT)
functions much in the same way as a quadrupole mass spectrometer, with some
differences. A quadrupole mass spectrometer works by alternating the polarity of four
rods creating a “saddle”, a stable region for ions of a certain m/z. The voltages and
frequencies can be adjusted to change which m/z will remain stable within the four poles.
The LIT works in a similar way with the addition of end caps which force the ions to move
back and forth within the analyzer, “trapping” them.23 LIT are also referred to as 2D ion
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traps as the ions move only in 2D and to differentiate them from the 3D Paul traps. The
primary advantage of using a LIT is that it allows for MSn. MSn Refers to the ability of a
mass spectrometer to fragment the ions then analyze the fragments and then fragment
them again to the nth degree of fragmentation and analysis. Theoretically this may be
done an unlimited number of times, but in reality, some sample is lost with each level of
fragmentation leading to lower and lower signals at higher levels.23 There are a wide
range of activation methods that can be used for fragmentation in LIT, but in our
experiments, we use collision induced dissociation (CID), whereby the ions are impacted
with a neutral collision gas, in our case helium, which causes the ion to fragment. There
are various methods by which these fragments will be analyzed/prioritized, to be
discussed below.
1.4 Data Analysis
1.4.1 Data Dependent MS
Two primary methods exist for data collection in bottom-up proteomics, Data
dependent analysis (DDA) and data independent analysis (DIA). DIA involves
fragmenting every ion seen in an initial scan. Because of the logistics of bottom-up
proteomics, these scans must be performed over a limited mass range. This process is
repeated until a full picture is gained. DDA works by only fragmenting specific ions within
the initial scan, which allows for much faster sampling, at the expense of some trace
ions.24,25 We use DDA in all of our analyses. In DDA the ions to be fragmented can be
chosen by a number of means, such as by picking the most abundant ions to fragment.
This technique is heavily dependent on the quality of the chromatographic separation, as
abundant ions can easily overwhelm the analysis if not properly separated. This can be
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improved further by techniques such as dynamic exclusion where ions of a certain mass
will not be fragmented again for a set period of time after having first been fragmented.25
Dynamic exclusion paired with DDA and high-quality chromatography is a very powerful
technique for proteomics analysis.
1.4.2 Proteome Discoverer
In our experiments we used the software Proteome Discoverer (Thermo Fisher
Scientific) for our proteomic analyses. Proteome Discoverer uses FastA files as a
“database” of proteins to search against. FastA files are commonly used for DNA code,
but Proteome Discoverer uses amino acid sequences instead, and are composed of a
simple list containing the names of proteins and the amino acid sequence using the one
letter codes. Consequently, Proteome Discoverer will only determine the confidence of
proteins that are listed in the FastA. This makes the analysis significantly faster and
easier, but means that potential contaminants, or unknown proteins, might be missed and
requires that the amino acid sequence of all the proteins be known in advance. Like all
bottom-up proteomics software, Proteome Discoverer compares the experimental
fragmentation spectra to computationally predicted19 fragmentation patterns and then
generates a confidence for the peptide, which is displayed as a color, with green being
high, yellow medium and red low. The peptides are then compared to the amino acid
sequence of the proteins in the FastA, which is then used to generate a “score” for the
protein. The exact formula used to calculate the score is proprietary, but it takes into
account a number of different factors. In addition to peptide confidence the program uses,
among other factors which are not displayed, protein coverage and unique peptides in
score calculations. Protein coverage is how much of a protein’s amino acid sequence was
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found in the sample and is expressed as a percent with 100% meaning that the entire
amino acid sequence was found in the peptides in the sample. “Unique peptides” refers
to peptide sequences that are found in the sample that are unique, or rare, to a certain
protein. The presence of these peptides increases the score.
1.5

Proof of concept experiments with T7 and E. coli

1.5.1 Summary of Our Previous Proteomics work
Prior to my starting on this project, our lab was able to successfully perform
proteomic analyses on bacteriophage infections. These analyses were performed using
methods similar to the ones used on our analyses of CrimD, which will be discussed in
Chapter 2. The original analyses were performed on E. coli infected with bacteriophage
T7. T7 genes are either “early” or “late” and we were able to distinguish between these
two types. These data show successful chromatography, and it should be noted that
different proteins are seen at different times in the table. Because our lab set up has been
previously shown to be successful, we believed that we could apply our set up, with
significant optimization to a different system: Mycobacteriophage CrimD.

Figure 1.2 Partial output screen from Proteome Discoverer and chromatogram showing
results from previous E. coli experiments. Note the tight peaks in the chromatogram,
indicating good separation.
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Single-stranded DNA-binding
protein gp2.5
OS=Enterobacteria phage T7
x
x
x
Phage shock protein G
OS=Escherichia coli
x
x
x
DNA ligase OS=Enterobacteria
phage T7
x
x
x
Endolysin OS=Enterobacteria
phage T7
x
x
x
Phage minor tail protein L
OS=Escherichia coli
x
x
x
Phage shock protein A, PspA
OS=Escherichia coli
x
x
x
Protein kinase 0.7
OS=Enterobacteria phage T7
x
x
x
Terminase, large subunit gp19
OS=Enterobacteria phage T7
x
x
x
Terminase, small subunit gp18
OS=Enterobacteria phage T7
x
x
x
x
Phage tail tape measure protein,
lambda family OS=Escherichia
coli
x
x
x
x
Protein 0.6B OS=Enterobacteria
phage T7
x
x
x
x
Phage-related tail fibre proteinlike protein OS=Escherichia coli
x
x
x
x
Prophage minor tail Z family
protein OS=Escherichia coli
x
x
x
x
DNA primase/helicase
OS=Enterobacteria phage T7
x
x
x
x
x
Table 1.1 Partial results from earlier analyses showing identification of different proteins
in bacteriophage T7 with x representing the protein being scored at that time point. The
time points represent time since infection. This table shows the ability to identify viral
proteins out of a vast quantity of bacterial proteins. We have improved on these results
with our analyses.
1.5.2 Motivation for This Work
Mycobacteria are the causative agents of tuberculosis and Hansen’s disease
(leprosy) among other infections. Understanding the bacteriophages that infect these
bacteria

is

critical

to

fully

understanding

these

diseases.

Research

into

mycobacteriophages has already yielded information about the bacteria leading to new
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advances in gene induction and other technologies.2 Having shown that we are able to
determine the timing of gene expression in T7 phages after infection of E. coli samples,
we took this as motivation for us to investigate the gene expression (proteome) of
bacteriophage CrimD. We believe that proteomics is the optimal method for studying
CrimD as it will allow us to see which proteins are actually expressed in vivo, as opposed
to simply studying the genome of CrimD. Chapter 2 describes the experimental methods
used in our study of CrimD proteomics and Chapter 3 describes our preliminary results
on CrimD protein expression.
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Chapter 2: Experimental Methods
2.1

General Workflow
We began our analyses of CrimD with infected mycobacteria samples prepared

for us by Prof. Williamson in the Biology Department. We processed these samples by
lysing the cells and then fractioning out the proteins. We digested the proteins into
peptides and analyzed the samples using high pressure liquid chromatography (HPLC)
coupled to MS. The data from these samples were analyzed using Proteome Discoverer
as described above.
2.2

HPLC-MS protocols

2.2.1 Overview
In our experiments we used nanoflow high performance liquid chromatography
(HPLC) combined with linear ion trap (LIT) mass spectrometry (MS) to perform all of our
analyses. These methods were chosen for a combination of availability of resources and
maximizing quality. Separation was based on reverse-phase chromatography. Our
chromatographic separation was accomplished via gradient HPLC with our solvent
gradient changing from a majority mixture of 98:2:0.1 high purity water: acetonitrile: formic
acid, hereafter referred to as solvent A, to a majority of 98:2:0.1 acetonitrile: high purity
water: formic acid, hereafter referred to as solvent B. Acetonitrile was chosen because it
acts as a good non-polar solvent and is readily available, but has a sufficiently high dipole
moment to dissolve some ionic or polar compounds. The formic acid was added to
protonate the sample and is necessary for ionization using NSI. The mobile phase was
transferred via 75 µm inner diameter x 355 µm outer diameter fused silica capillary
produced by Polymicro. The autosampler used exclusively solvent A to perform the
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sample injections. After each sample injection, we would do a repeat with a blank, usually
high purity water, using an identical injection procedure. This was done in order to catch
any peptides that were missed in the initial analysis. A further flush was then run in order
to guarantee no carryover between injections. Over the course of my work on this project
our protocols have changed dramatically.
2.2.2 Previous experimental protocols
2.2.2.1 Analytical columns and NSI emitters
When I began work on this project, all analyses were performed using an Eksigent
nano-LC2D nano UHPLC paired with an Exigent autosampler. This HPLC is capable of
2D analysis and we initially used this functionality to transfer the analyte from the
autosampler to a 3 cm C-18 guard column, in this case acting as a precolumn produced
by Thermo Fisher. The guard column acts as a sort of filter to improve our signal. The
column is a short, very non-polar column onto which the analyte is run. The sample is
loaded onto the trap column at 100 nL/min flow rate and then a switching valve allows for
backflow elution of the sample from the trap column onto the packed analytical column
for separation. Use of the trap column has two benefits. First, our sample is compacted
into a smaller “packet” for analyses. The smaller the packet that hits the analytical column,
the better the separation will be. Secondly, very polar species, including most
contaminants are not retained in the guard column, thus cleaning up the sample.
Unfortunately, this also can cause a loss of the most polar peptides from the sample. As
the ultimate goal is protein identification, losing some of the most polar peptides is an
acceptable loss if it ensures that the contaminants are removed.
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Our analytical columns were initially purchased commercially; an example includes
the EASY-column produced by Thermo Scientific. These columns were made by placing
a frit at one end of a glass capillary then filling the capillary with a bead that would act as
the stationary phase. The frit is a semi-porous membrane that allows the mobile phase
and any analyte contained within to pass through but does not allow the stationary phase
to pass through. These columns, though effective, had wildly varying working lives,
ranging from weeks to minutes. The inconsistency combined with the monetary cost of
the commercial columns meant that their use was not sustainable.
The emitters used in our early experiments were fused silica capillary that had
been pulled into the shape of a needle. The needles are typically around 1-2mm long with
a final tip diameter of <5 um. Initially, we purchased these tips commercially from New
Objective. These tips frequently had intermittent flow, that is, the flow during injections
would cut out periodically, usually around every minute, before resuming. During the time
when the spray was not functioning all signal was effectively lost. These emitters would
also frequently clog. A clog manifests as a total lack of flow from the emitter and with a
large spike in back pressure, usually on the order of around 2,000 psi, which would cause
the pumps to exceed their maximum capacity and proceed to shut down. The needles
clogged frequently, but there appears to be no pattern as to when or how the emitters
clogged.26
Results from experiments that used the Eksigent autosampler and HPLC were
inconsistent. Some sample runs would have what appeared to be excellent separation,
while runs done with the same column less than 24 hours later would have very poor
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separation, with most settings being held constant. I suspect that the cause of this was
issues with the autosampler and flow settings of the nano-flow pumps.

Figure 2.1 a and b 2 Chromatograms from around 2 weeks apart run with the same
sample with identical settings, but different columns that were prepared at the same time
as each other. Note the clean separation in a, contrasts with b where the separation is
basically non-existent. The exact cause of the dramatic changes in quality remains
unknown.
2.2.2.2

Loading optimization

Over the course of my work on the project, we attempted several experiments
without the guard column. In these experiments the initial signal in the mass spec was
very high, but many less-abundant peptides were missed due to saturation with the more
abundant peptides. By removing some of the very polar peptides using the guard column,
we were better able to analyze less abundant peptides. In addition, the chromatographic
separations without the guard column were invariably very poor.
The Eksigent autosampler initially used when I began work on this project had
some significant drawbacks. We were ultimately unable to calibrate the flow meters to a
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high accuracy. We incorrectly assumed that the lack of accuracy was largely
inconsequential as the flows simply needed to be consistent relative to each other, which
they were. What was made difficult by this lack of precision was loading the trap columns.
The sample loop in the auto sampler had a set volume and transferring that volume onto
the autosampler became a difficult balancing act between not loading it onto the column
at all, versus running our sample too far on the trap column, which significantly hurt
separation. The inconsistent flow rates also caused issues with injection, where multiple
injections of a set volume were always the same as each other but were generally not
proportional to the set volume. We never successfully loaded the guard column using the
Eksigent with any consistency. The Shimadzu HPLC (see section 2.3) system was far
more precise with its injections and flow rates, which proved crucial in optimizing our
analyses.
2.3

The switch back to microflow-HPLC and ESI
A mechanical failure in the Eksigent autosampler required us to switch to a

different HPLC instrument, a Shimadzu LC-20A, which is unfortunately not capable of
flow rates on the order of magnitude required for nano-spray ionization. The typical flow
rates for this instrument are on the order of microliters/min – mL/min, around 1-3 orders
of magnitude higher than the nanoflow HPLC. These flow rates precluded the use of the
nanoflow column, without use of additional plumbing. The primary downside of the higher
flow was that orders of magnitude more solvent were needed when compared to the
nanoflow system, which increases the cost and the environmental impact of our
experiments. In addition, we lost the benefit of the aforementioned advantages of NSI.
The microflow system did have some inherent benefits, though. The higher flow rate
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reduced the risk of columns becoming clogged, which made it economical to purchase
larger stainless-steel columns commercially that have a known and tested functionality.
Our particular microflow system had the added benefit of integrating a UV-VIS detector
and a column oven into the instrument set up. The UV-VIS detector is a form of absorption
spectroscopy that allows us to visualize the sample in the column output separately from
the MS. This spectroscopy dimension added a level of certainty to our data as we could
verify peaks as being present in the MS and UV-VIS, and aided in trouble shooting, as a
peak in one detector and not the other was a good indication of a potential issue. In our
experiment we monitor absorbance at 254 nm. This number was chosen based on
literature values that demonstrated a balance of good absorption of peptides with a low
absorption of acetonitrile.27 The column oven maintained a constant temperature of 40°
C on the column. The increased temperature increases the rate at which the sample
dissolves into the stationary phase, improving the separation. This system was used
initially with an electrospray ionization source (ESI) with a heated probe. The heated
source was used to help with the large volume of sheath gas that was required for this
flow rate. We initially did not use the guard column arrangement for this instrument and
instead injected directly onto the analytical column.
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Degasser
Pump A
Pump B
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UV/VIS
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Figure 2.2- Diagrams of both instruments labeled with their different components. Left is
the Shimazu LC20A system and the Eksigent nano LC2D is on the right. Not pictured in
the Shimadzu diagram is the column oven, additionally the UV/Vis pictured is a different
model, though they are superficially identical. The rack changer pictured is present, but
not used in our set up. The Eksigent is not modular and hence all pumps/ control system
are housed in a single unit.28,29
We attempted to perform some test analyses using the microflow system however,
all of these experiments presented significant problems. We were able to see a high
coverage of the proteins, that is, we could detect a majority of the peptides in a majority
of the samples in our test solutions, but the confidence for these peptides and the protein
scores were very low. Ultimately, the advantages of NSI required us to modify the
Shimadzu plumbing system to allow for the generation of nL/min flow rates while still
maintaining the ability to create specific solvent gradients. This change required the use
of a flow “splitter”. This device, a model 620 produced by ASI, works by a similar method
to an electric resistor. The flow is split into 2 directions and passed through two cartridges
that limit the rate of flow through them, which allows for the generation of accurate flow
rates in the nL/min range without using nanoflow pumps. It is important to note that the
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total solvent used does not change with the splitter. The results from these experiments
proved similar to the results we got when we used the nanoflow without the guard column.
2.4

Our current protocols
Over the course of our work, we have changed many of our protocols to optimize

them better for this set up. We have faced many disappointments but have arrived at a
point where we are able to perform our analyses consistently. We can reproducibly
produce tips, columns and digest samples and successfully analyze them with the HPLCMS.
2.4.1 Biology protocols
2.4.1.1

Cell lysis and protein extraction

Our samples were prepared by inoculating Mycobacterium smegmatis with the
previously characterized phage, CrimD. The phages were allowed to grow in the sample
for a specified amount of time and then were frozen at minus 80° Celsius to arrest growth.
The times chosen were 30, 60 and 150 min post infection, and were chosen to help
elucidate the timing of the genes as early or late. All of the previous steps were carried
out by Professor Kurt Williamson, or by a student working in his lab. The samples were
taken from the lab and lysed using the Pierce Mass Spec Sample Prep Kit for Cultured
Cells produced by Thermo Fisher
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. In this method the cells are first pelleted using a

centrifuge then lysed by re-suspending the pellet with a detergent-based cell lysis buffer,
with TritonX-100 acting as the detergent. The resuspension was incubated at 95o C for 5
min. The nucleic acid components of the cell are sheared using a sonicator produced by
Qsonica. This is done in order to reduce the viscosity of the sample. The solution is then
centrifuged at 16000 g for 10 min, with the proteins largely remaining in the supernatant.
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The concentration of proteins in the supernatant is confirmed by use of a Nanodrop
produced by Thermo Scientific

Figure 2.3. Flow-chart illustrating our digestion process from the protocol that was
included with our commercial protein digestion kit 30
2.4.1.2

Protein Digestion

Following protein extraction, the proteins are reduced and alkylated, by use of
dithiothreitol (DTT) and iodoacetamide (IAA) respectively, to disrupt the tertiary structure
of the proteins. DTT reduces the exposed disulfide bonds formed between cysteine
residues that make up the tertiary structure, resulting in thiol groups being formed in place
of the sulfide bonds. IAA then alkylates the thiol groups to prevent reformation of the
disulfide bonds. This process includes incubating the proteins with DTT for 45 min at 50°
C and then incubating with IAA for 20 min at room temperature. IAA is light sensitive, and
this reaction is performed in the dark. The proteins are then precipitated out of the
digestion buffer by mixing with acetone at -20° C overnight. The proteins are further
purified by centrifugation and additional rinses with chilled acetone. The purified proteins
are then re-suspended in a digestion buffer and digested first by Lys-C and then by
trypsin. The digestion buffer, in combination with temperature, denatures the proteins,
which allows enzymatic digestion to progress. Lys-C is a protease that cleaves primarily
C-terminal to lysine residues, while trypsin is a protease that cleaves C-terminal to both
lysine and arginine. The combination of enzymes is used as it has been found to have a
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low number of missed cleavages, that is un-cleaved residues that act as targets of the
digestion enzymes.31 Lys-C digestion takes place at 37° C for 2 hours while the trypsin
digestion takes place at 37° C overnight. Digestion is arrested by freezing at -80° C and
proteins samples were stored at this temperature until ready for analysis. Before analysis
the proteins were concentrated using a Savant DNA 120 SpeedVac Concentrator
produced by Thermo Scientific then re-suspended in solvent A, as previously described,
and frozen at -20° C in preparation for analysis.
2.4.2 HPLC parameters and gradient
The autosampler is set to inject a user-specified volume and then rinse the needle
and purge the lines between each run. This, in addition to the blank runs, helps to
minimize any carryover between runs. The primary runs and the blank runs had slightly
different gradients. The microflow pumps we set to a total flow rate of 1 ml/min. After the
splitter this becomes 1 µl/min (1000 nl/min). The gradient features 95% solvent A for 45
min followed by a ramp down to 55% solvent A for 45 min. This is then followed by a
gentle ramp to 30% solvent A for 60 min followed by a sharp ramp to 5% solvent A for 20
min. The column is then washed for 10 min by quickly ramping back up to 95% solvent
A. This results in a 180 min run total. The blank runs start with 95% solvent A for 5 min
then have a quick ramp to 65% A for 10 min followed by a gentle ramp for 45 min to 30%
A and a 5 min ramp to 5% A. The flush concludes with a 15 min wash for a total time of
75 min. The reasoning for the difference in gradients between the blank and sample runs
was originally time: blanks were not originally expected to be worth investigating and thus
were made shorter to speed up the analysis. When we discovered that the flush did
regularly have high confidence proteins, we tried different gradients that all yielded
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roughly equivalent results to the ones discussed above. Because of the apparent
equivalence we reverted to the original gradients.
2.4.3 Analytical columns
In order to mitigate the cost of purchasing pre-made columns we began
manufacturing our own packed analytical columns. We did this by producing a frit similar
to that used commercially. Our frits were made in one of two ways. One method includes
mixing a potassium silicate (Kasil) mixture produced by PQ Corporation with formamide
and dipping a capillary directly into the solution. The capillary was then baked at 500 °C
overnight. The resulting frits were often far too long to use and needed to be cut down
the ideal length of around 1-3mm, which proved difficult as the frits are all but impossible
to see except under a microscope and cutting the capillaries is, at best, an imperfect
science. The second method of producing frits involves dropping the Kasil-formamide
mixture onto a small piece of filter paper and then aggressively tapping the end of the
capillary against the filter paper. Capillary action would then draw some of the mixture
into the capillary and would also draw some of the filter paper into the capillary. The frit
was then heated briefly, less than 10 s, with either a butane or propane torch. The frits
made by this method were of much higher quality than the previous method, but the
method had a very low yield. Occasionally as few as 1 in 3 capillaries would actually make
a usable frit. Both of the previously described methods were adapted form methods
originally developed by the University of Washington Proteomics Resource Center
(UWPR).32 The fritted capillaries were then “packed” using a method also developed by
the UWPR. In this method the capillaries are placed in a “bomb”, which is a small brass
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container that can be sealed except for two openings for allowing high pressure helium
gas into and out of the bomb.

Figure 2.4 Figures from UWPR protocol for producing columns. Left shows the production
of a frit and right shows the “bomb” for packing the columns. The flame pictured is different
from that used in our protocols but is otherwise the same. The figure on the right closely
matches our protocol. 32
The capillary is placed in one inlet with the end of the capillary opposite the frit
placed into an open container full of slurry containing the packing material. The other end
is exposed to the air. The second inlet is used to vent in helium under high pressure,
around 1,000 Psi. This forces the slurry through the capillary where the packing material
is stopped by the frit, but the liquid and helium gas pass through. In our method we use
methanol as the liquid in the slurry and our packing material is Zorbax 5-micron C-18
beads, produced by Agilent. Our method can be used, in theory, to produce analytical
columns as long as 40 cm

32

, but we have been unable to reproducibly make columns

longer than ~15 cm. The reason behind this is that the capillaries can become “clogged”
during the packing process, and any time after. The exact reasoning for this remains
unknown26, but in our experience longer columns clog more frequently. We have made
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various attempts to rescue clogged columns, but to date all have failed, and clogged
columns were discarded. The column is then placed onto the nanospray source, made
by New Objective and is connected to an emitter.
2.4.4 Nanospray emitters
Due to the costs of the commercial emitters, we purchased a laser pipette puller,
a model P-2000F produced by Sutter Instrument Company. This instrument allows us to
produce our own emitters in-house at a significantly reduced cost. Initially, our success
rate for producing working emitters was as low as 15%, from the initial number of
capillaries prepared to the number that functioned as emitters, but we have successfully
increased our skill to the point where we can reliably produce working tips consistently.

Figure 2.5 Sutter P2000 pipette puller. The black object in the center of the assembly is
the housing for the laser. The mechanism on either side is the arms that hold and pull
the capillary into the needle shape.33
Pulling our own emitters has allowed us to change our column preparation method
as well. This pipette puller works by using a laser to heat up the center of the glass
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capillary while applying pressure to either end. The causes the capillary to thin in the
middle and eventually separate into two approximately equal emitters. We no longer
need to rely on separate fritted columns as we can now produce emitters that have empty
capillary of sufficient length behind them to be packed in the same way as a fritted column,
thus creating a single packed column/emitter device.
While using the packed emitters dramatically increases the speed and success
rate when producing new columns, this switch in protocol has the unfortunate side effect
of reducing the working life of our columns. When the emitter clogs the entire column is
now unusable. For most of the experiments described, we used columns with the
attached emitters, but in an effort to produce longer columns some experiments were
attempted with fritted columns. These ultimately failed, and all of the final analyses of the
CrimD samples were performed using integrated columns and emitters. The tips and the
columns are ultimately identical from one to the other, and the frit is not thought to have
any impact on the sample so the two can be thought of as equivalent.
2.4.5 Mass spectrometer parameters
All experiments were performed on a Thermo LTQ XL linear ion trap mass
spectrometer. In our experiments we used a spray voltage that was dependent on the
needle and source, typical ranges are 1.75- 2.75 kV for the NSI. We used a mass range
of 350-2000 m/z. We chose this range to eliminate as many contaminants as possible
that have lower masses, while maximizing the number of peptides that would be
observed. We used a DDA dependent scan system, with an isolation width of 2 m/z,
where for each full scan the 4 most abundant ions in that scan would be fragmented. The
scanning range in the dependent scans was increased to 110-2000 m/z as many
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fragments had lower masses. They were fragmented by CID with a normalized collision
energy of 35 (out of 100), an activation Q of 0.250, and an activation time of 30 ms. We
used dynamic exclusion with masses being rejected after being seen three times within
60 seconds. Up to 200 masses can be excluded at any given time and they remain on
the exclusion list for 180 seconds. Dynamic exclusion used a scanning width of +/- 1.5
m/z. These methods were developed based partially on methods given to us by the
University of Arizona Proteomics Lab and were modified based on our specific
experimental design.
2.4.6 Proteome Discoverer protocols
For our analyses in Proteome Discoverer, we use a workflow that was originally
developed for use in bacteriophage T7 with E. coli. The workflow has been slightly
modified to accommodate the CrimD analyses. The workflow is configured to work with
our specific instrument. Our workflow uses a default minimum precursor mass of 350, and
a default maximum of 5000. 350-5000 m/z range is larger than the mass range used on
the MS in our experiments. This was left bigger as we did not see any harm in keeping
the Proteome Discoverer range constant when the MS range was reduced. We worked
under a tolerance of +/- 1.5 Da for the precursors and +/- 0.6 Da. These parameters are
based off parameters given to us by the University of Arizona and have been slightly
modified to optimize results. In our peptide fingerprinting we only looked for b and y
fragment ions. This naming system is based on where in the peptide backbone the
peptide is fragmented.34 Ions of b- and y-type correspond to fragmentation on the peptide
bond. The letters “b” and “y”” refers to which fragment retains the charge after peptide
bond cleavage. We assumed a minimum peptide length of 6 and a maximum of 144.
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Proteome discoverer works under the assumption of a single enzymatic digestion, for this
reason we use trypsin as it also cleaves at the site preferred by Lys-C. We included 3
dynamic modifications to our peptides; dynamic in this instance means that this particular
modification may or may not be present, while static means that modification is always
present. These were N-terminal acetylation, C-terminal oxidation and methionine
oxidation. We included one static modification: cysteine carbamidomethylation a result of
the DTT and IAA processing. These were also based originally on the parameters
provided to us by the University of Arizona proteomics lab.
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Chapter 3.

Results and discussion

I investigated the timing of the expression of gene products in CrimD to determine
when each gene is active within the viral replication cycle. CrimD has 95 genes of which
21 have identified functions. We determined the time of expression, relative to the phage’s
life cycle, of some of these genes.
3.1

Identified proteins from CrimD

3.1.1 Scored Proteins
In total, 75 proteins were successfully identified for the time-values across several
analyses. For the purposes of this discussion successfully identified will be defined as
having a score of greater than zero in Proteome Discoverer. Due to time constraints,
complete statistics have not yet been performed on this data and these values do not
have confidence intervals associated with them. More than 20 sample runs were
analyzed, but 2 failed to have any proteins with a score. A sample run consists of a
primary run where the sample is injected or a flush run immediately after. The flush, or
blank, consists of a similar protocol as the sample run with the exception that instead of
sample, water was injected.
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Figure 3.1. Chromatograms from a T30, above, and T150 run, below. The T30 run is a
sample run and the T150 is a blank. The red lines represent the presence of a peptide, in
this case the most confident peptide from the highest scored protein. Note the tight band
in the T150 compared to the more spread out T30. The gaps in the T30 (from 50 min to
90 min) are due to the dynamic exclusion.
It is strongly suggested from our chromatographic data that we are loading too
many peptides onto our column, i.e., the concentration of the sample is far too high. This
is believed to be the cause of the poor-quality chromatograms during our sample runs but
the high concentration of peptides results in high protein scores. The flush runs analyze
residual peptides, and therefore have far better chromatograms, but have slightly lower
scores due to the lower peptide concentrations. Since we are analyzing both sets of data,
we feel confident in the assignment of the proteins from the different time points despite
having inefficient chromatographic separation in the primary runs. We are currently
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optimizing our sample injection protocols in order to avoid overloading the column but
due to time constraints those data are not in this document.
Proteins are either listed as a number, i.e., 24, which represents a protein whose
function has yet to be identified, or as the hypothetical function of the protein. Several
proteins have the same function, for example the minor tail subunit, for the purposes of
clarity we labeled these proteins as a or b.
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Table 3.1 showing proteins found in the three time intervals. The percent refers to what
percent of runs had the given protein, CrimD_xx denotes protein without known function,
and the number represents the gene number as it is listed in the genome, posted on
PhageDB.org
Table 3.1 shows all of the proteins found in our analyses. The major capsid protein
was the highest scored protein in the majority of the T150 runs and was scored much
lower in the T30 and T60 runs. The Capsid Maturation protease/ MuF like Minor capsid
subunit (CMP/MMCS) is a protein whose gene belongs to a phamily, a group of related
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phage genes, which serve one of those two functions. CMP/MMCS was the highest
scored protein in a majority (6/11) of the T30 runs and one of the T150 runs. The T150
and T60 runs had consistently higher scores on average for the most abundant proteins,
this was mostly due to the blanks from the T30 runs having very low scores overall. The
T150 and T60 runs consistently had higher scores in the blank run than in the sample
runs.
3.2

Discussion
In analyzing these data, it is important to note that these samples contain millions

of cells and potentially billions of proteins. The replication cycle for the phages infecting
these cells is not perfectly uniform. At any given moment some cells might be uninfected,
while others are in the lytic phase, though efforts were made to minimize this. The data
are collected from the whole culture and therefore any variations in cell growth will be
seen in the data. We believe that this is the reason that some proteins that are typically
involved in the lytic replication cycle are being seen, albeit with low scores and not
consistently, in the T30 runs.
Capsid maturation proteins are proteins that cleave immature capsid proteins to
yield mature capsid proteins, while MuF-like proteins are a type of toxin.35 MuF proteins
are often included in the capsid and injected into the cell with the viral DNA, but their exact
purpose is not fully understood.35 One of the proposed functions of MuF toxins is to inhibit
cellular growth in the surrounding bacteria. Because CMP/MMCP is incorporated into the
capsid, its higher scores at the T150 time sample are also unsurprising.
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Figure 3.2 Graph comparing the average score of the CMP/MMCP in the different time
points. Runs that had at least one scored protein where CMP/MMCP was not scored were
counted as a 0.
We also suspect protein Unknown 74 to be involved in the lysogenic replication
cycle as it is also present early in the viral replication cycle. Integrase, which is responsible
for integrating the phage genome into the host genome, is also related to lysogenic
replication. Another protein of note is the RtcB protein found in the T30 and T60 runs.
This protein functions to circularize RNA molecules by linking the 5’ and 3’ ends together.
This functionality plays a role in the synthesis of tRNAs.36 Its presence in the earlier time
sample is consistent with its functionality and we suspect it is involved in the lytic
replication cycle.
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Figure 3.3 Graph comparing the average score of the CrimD 74 in the different time
points. Runs that had at least one scored protein where CrimD 74 was not scored were
counted as a 0. CrimD 74 is suspected to be involved in the lysogenic replication cycle
based on its higher score in the T30 runs. Of note though, CrimD 74 was present in a
higher portion of T60 runs than T30 runs (75% vs 64%).
The presence of the major capsid protein and Lysin A in the T150 samples strongly
suggest that the phage has entered the late lytic part of its replication cycle. This would
suggest that the proteins that are predominantly in the T150 samples are primarily
involved in the later lytic replication cycle. The major capsid protein was the dominant
protein in the T150 samples and was also scored far lower, when scored at all in the other
runs. Major capsid protein is, of course, the major component of the viral capsid and
during lytic replication it would become one of the most produced proteins in the cell in
preparation for cell lysis.
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Figure 3.4 Graph comparing the average score of the major capsid protein in the different
time points. Runs that had at least one scored protein where major capsid protein was
not scored were counted as a 0. The major capsid protein is involved in the lysogenic
replication cycle and this graph suggests that the vast majority of cells are in the lytic
replication cycle at the T150 time point while far fewer are lytic at T30 or T60.
Based on the proteins observed in the T60 time point it is less obvious which phase
of phage replication a majority of the cells are in. The high scores of the viral DNA helicase
in the T60 time point, in the graph below, combined with its ubiquity, it was present in
every T60 run, suggests that the virus has begun to replcate its genome. Viral helicases
are a very common feature of DNA viruses and some RNA viruses. They play important
roles in regulating the viral replication cycle, and significant diversity exists between
different viral helicases, though many do share a common origin.37
CrimD DNA primase/helicase is likely involved in the replication of the viral
genome. Because the lysis proteins and capsid proteins are not as highly scored or widely
present in T60 as opposed to T150 we believe that the CrimD is in the early lytic
replication phase during the T60 time sample. During this phase the virus predominantly
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replicates its genome while lysing the host genome. We believe that any unknown
proteins predominantly present in the T60 time samples, such as CrimD 90 or 48, are
proteins involved in DNA replication

Average Score for DNA primase/helicase
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Figure 3.5 Graph comparing the average score of DNA helicase in the different time
points. Runs that had at least one scored protein where DNA helicase was not scored
were counted as a 0. The DNA primase/helicase is involved in viral genome replication.
We believe that its presence predominantly in T60 suggests that CrimD is in the early lytic
phase of its replication cycle.
3.3 Conclusions
Here we have described the proteomics analysis of mycobacteriophage CrimD.
CrimD was previously characterized as part of the William & Mary Phage Lab. We took
the next logical step of full proteomic analysis. Although we have been able to perform
proteomic analyses on bacteriophages previously, our set up required much optimization
to be able to function sufficiently well to perform these analyses. We analyzed three time
points in the CrimD life cycle measured from time of infection. These time points
correspond to Early, Middle and Late genes respectively. We identified 75 bacteriophage
proteins and determined in which time points each of those proteins was expressed. We
40

believe that the next step in the work is bioinformatics to begin to assign functions to some
of the unknown proteins and further characterize mycobacteriophage CrimD.
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